Vanrx introduces quality assurance technology
November 3, 2015 - News
Vanrx Pharmasystems will be presenting its new vision targeting system at PDA event to demonstrate how its accuracy and efficiency benefits drug manufacturers.
• Vanrx vision targeting system is unique technology that uses isolated robotics in the inspection of entire nests of vials, syringes and cartridges, and their corresponding closures, ensuring quality checkpoints and eliminating human error.
• The technology creates a cost effective and efficient process by using a high definition imaging system that is able to sense when components are missing from a ready-to-use nest, allowing Vanrx isolated workcells to reject defective components.
• Vanrx will be presenting a live demonstration at this year’s PDA The Universe of Pre-filled Syringes and Injection Devices event on November 3rd, 2015 in Vienna, using Schott’s ready-to-use nested solutions.
Vienna, Austria – PDA 2015 (November 2nd, 2015) — Vanrx Pharmasystems will be introducing their isolated high definition vision targeting system at this year’s Parenteral Drug Association’s (PDA) ‘The Universe of Pre-filled Syringes and Injection Devices’ conference. This technology further supports Vanrx’ isolated robotics technology in providing a seamless process of fill-finishing injectable devices. In combination with Vanrx’ gloveless filling process, the technology completely eliminates the need for human interference. This revolutionary technology inspects nested vials, cartridges, syringes, and their corresponding closures, to provide a more accurate, cost-effective and efficient filling process.
“Eliminating extra steps with filling combination systems is key to increasing production speeds while also removing the risks that come with using traditional filling processes,” says Mr. Chris Procyshyn, chief executive officer, at Vanrx. “Vanrx strives to be proactive in providing innovative solutions that will improve how drugs today are manufactured. We are excited to now be able to provide a seamless process from start to finish and look forward to showcasing our new technology at the PDA event with Schott.”
“The pharmaceutical manufacturers are in need of more efficient processes that will ensure that the quality of medicine is met through using superior materials and reliable technology,’ states Mr. Anil Busimi, head of global product management, Syringe Business at SCHOTT Pharmaceutical Systems. “Vanrx’ compatibility with our (Schott) nested solutions like prefillable syringes helps drug manufacturers reduce potential product loss by being able to simplify the filling process. We are keen to see this technology in action at the PDA event.”
Using isolated, high definition imaging, the vision targeting system is able to sense when components are missing from ready-to-use nests, allowing Vanrx technology to reject defective components. This quality assurance check prevents defective nests from continuing onto the filling process, removing the risk of filling a void, potentially costing manufacturers 1ml-50ml of expensive medicines.
Vanrx will show their innovative high definition imaging solution with SCHOTT at this year’s PDA The Universe of Pre-filled Syringes and Injection Devices event to demonstrate how the vision targeting technology works in providing a more efficient and accurate quality assurance process. While they will be showcasing using Schott’s ready-to-use nested solutions, the technology is easily adaptable to different nest sizes. For more information on Vanrx technology, please take a look around our website.